IRIX Earnings Prediction
The chart below shows how IRIX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IRIX sees a +9.88% change in stock price 10 days leading up to the earnings, and a -0.38% change 10 days following the report. On the earnings day itself, the stock moves by -1.76%. This data can give you a slight idea of what to expect for the next quarter's release.
IRIX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.58M
-9.88%
-8.31%
Gross Margin
37.33%
-14.65%
-8.17%
Operating Margin
-16.15%
22.91%
-22.69%
Net Margin
-16.69%
22.27%
-21.31%
EPS
-0.12
-9.09%
-25.00%
No Data Available
IRIX Earnings Analysis
Iridex Corp Corporation (IRIX.O) Earnings Conference Call
Positive
Third Quarter Revenue Decline: Total revenue in the third quarter of fiscal '24 was $11.6 million, representing a 10% decline compared to $12.9 million in the same period of the prior year.
Cyclo G6 Revenue Increase: Total revenue from Cyclo G6 product family in the third quarter was $3.1 million, an increase of 3% versus the third quarter of '23, driven primarily by stabilization of probe sales on improved clarity on the glaucoma procedure reimbursement environment in the US.
Cyclo G6 Probe Sales Decline: We sold 13,600 Cyclo G6 probes in the third quarter, representing a sequential decline of 10% compared to the second quarter of '24, consistent with seasonal decline in probe volumes we experienced in the third quarter.
Retin A Revenue Decline: Our retin a segment revenue in the third quarter of '24 was $6.5 million, down 18% compared to the third quarter of '23.
Gross Profit Comparison: Gross profit in the third quarter of 2024 was $4.3 million compared to $5.6 million in the prior year period.
Negative
Third Quarter Revenue Decline: Total revenue in the third quarter of fiscal '24 was $11.6 million, representing a 10% decline compared to $12.9 million in the same period of the prior year.
Cyclo G6 Revenue Decline: Total revenue from Cyclo G6 product family in the third quarter was $3.1 million, a sequential decline of 10% compared to the second quarter of '24.
Retina Segment Revenue Decline: Our retinas segment revenue in the third quarter of '24 was $6.5 million, down 18% compared to the third quarter of '23.
Gross Profit Decline: Gross profit in the third quarter of '24 was $4.3 million compared to $5.6 million in the prior year period, reflecting a decline in gross margin from 43.7% to 37.3%.
Quarterly Net Loss Comparison: Our net loss in the third quarter of '24 was $1.9 million or $0.12 per share compared to a net loss of $1.8 million or $0.11 per share for the same period in '23.
IRIX FAQs
How does IRIX typically perform around its earnings report dates?
Is IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IRIX Earning Call Sentiment
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IRIX.O
0.21%Positive
The earnings call reveals a challenging financial performance with declining revenue and margins, offset by cost-cutting measures. The strategic review and leadership change indicate uncertainty, and regulatory hurdles pose risks. Despite optimistic guidance and potential transactions, the market may react negatively due to prolonged strategic review and financial struggles. The Q&A section lacks clarity, further affecting sentiment.